Specifically, in asymptomatic patients, Goldberg et al9 reported median iPFS of 2.3 months among NSCLC patients who had ≥1% PD-L1 expression and Flippot et al11 reported median iPFS of 2.7 months among RCC patients who had previously untreated BM. This evidence concerns the gene CD274 and non-small cell lung carcinoma.